The Phase 1 data readout in Q2 2027 is the next major catalyst. The $20M milestone closing provides near-term funding certainty but adds dilution (~35M shares/warrants). Monitor enrollment updates and any early safety signals.
Price Chart
Executive Summary
Equillium dosed the first subject in a Phase 1 trial of EQ504, an oral AhR modulator for inflammatory diseases, triggering a $20M milestone closing under its August 2025 equity private placement. The company expects to report topline Phase 1 data in Q2 2027 and has cash runway into 2029.
Key Financial Metrics
Key Facts
- First subject dosed in Phase 1 trial of EQ504 (oral, colon-targeted AhR modulator) in Australia.
- Phase 1 trial is randomized, double-blind, placebo-controlled, enrolling ~70 healthy subjects.
- Topline proof-of-mechanism data expected in Q2 2027.
- Milestone closing of $20M in additional funding under August 2025 equity private placement triggered.
- At closing, Equillium will issue ~14.96M shares at $0.57/share and ~20.13M pre-funded warrants at $0.5669/warrant.
- Total private placement proceeds expected to reach ~$50M; cash runway into 2029.
- Company plans to initiate a placebo-controlled proof-of-concept study in ulcerative colitis in H2 2027, subject to Phase 1 data.
Financial Impact
$20M milestone closing brings total private placement proceeds to ~$50M; cash runway extended into 2029.
Risk Factors
- Phase 1 trial may fail to demonstrate proof of mechanism or acceptable safety/tolerability.
- Dilution from the milestone closing (14.96M shares + 20.13M pre-funded warrants) could pressure the stock.
- Competition in the inflammatory bowel disease space is intense; EQ504's differentiation is unproven in humans.
- Cash runway into 2029 depends on assumptions that may change with trial results or development plans.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3388089 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $1.29 | awaiting T+60 | — | $1.25 (+3.10%) |
Oct 26, 2026 1d ago | Press Release | $1.25 | awaiting T+60 | — | $1.25 (0.00%) |
Oct 5, 2026 22d ago | 8-K | $1.42 | awaiting T+60 | — | $1.25 (−11.97%) |
Oct 5, 2026 22d ago | Press Release | $1.42 | awaiting T+60 | — | $1.25 (−11.97%) |
Sep 29, 2026 28d ago | Press Release | $1.63 | awaiting T+60 | — | $1.25 (−23.08%) |
Jun 11, 2026 19w ago | Institutional Cluster | $2.81 $2.21 | ▼ −21.35% | ▼ −25.75% | $1.25 (−55.52%) |
Jun 5, 2026 20w ago | Insider Cluster | $2.77 $2.21 | ▲ +20.40% | ▲ +23.45% | $1.25 (+54.87%) |
May 29, 2026 21w ago | Insider Cluster | $3.08 $2.18 | ▼ −29.22% | ▼ −30.45% | $1.25 (−59.42%) |
May 20, 2026 22w ago | Press Release | $2.21 | awaiting T+60 | — | $1.25 (−43.44%) |
Apr 17, 2026 27w ago | EFFECT | $2.05 $2.76 | ▲ +34.63% | ▲ +28.49% | $1.25 (−39.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers